Donor Innate Lymphocyte Infusion Product for Immunotherapy of Glioblastoma Multif
Donor Innate Lymphocyte Infusion Product for Immunotherapy of Glioblastoma Multif
批准号:
7772397
负责人:
LAWRENCE S LAMB
金额:
$18.31万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-03-01 至 2012-02-28
关键词:
AdjuvantAllogenicAntigen-Presenting CellsAutoantigensBiological AssayBloodBrain NeoplasmsCell LineCell TherapyCellsClinicalClinical ProtocolsDataDevelopmentDiphosphatesEffector CellGlioblastomaHumanImmuneImmune responseImmune systemImmunotherapeutic agentImmunotherapyIn VitroInduction of ApoptosisInfusion proceduresInterferon Type IIInterleukin-12Interleukin-2LaboratoriesLymphocyteMalignant neoplasm of brainMethodsMigration AssayMinorMusNatural Killer CellsNitrogenNude MicePatientsPeptidesProceduresProcessProductionProtocols documentationPublishingReagentRegimenRegulationReproducibilityResearchResistanceStagingStressT-Cell ActivationT-LymphocyteTestingTherapy Clinical TrialsTranslationsTumor BurdenTumor Cell LineUnited States Food and Drug AdministrationWorkXenograft ModelZoledronateantigen processingbasebisphosphonatebrain tissuecancer therapycell growthcell mediated immune responseclinical applicationcytokinecytotoxiccytotoxicityeffective therapykillingsmanufacturing processneoplastic cellprogramspublic health relevancescale uptumortumor xenograft
中文摘要
描述(由申请人提供):尽管在过去几十年中在癌症治疗方面取得了显著进展,但对于多形性胶质母细胞瘤(GBM)没有长期有效的疗法。我们的实验室最近在体外和小鼠异种移植模型中显示了有希望的发现,即人GBM容易受到局部递送的同种异体先天性淋巴细胞治疗的影响。这些拟定研究将确定FDA批准的细胞治疗产品的生产方案,该产品主要由扩增/活化的34 T细胞和少量NK细胞亚群组成,用于GBM的辅助免疫治疗。最近已经公布了用于免疫学应用的34 T细胞的大规模扩增的几种潜在方法。这些方法包括使用临床批准的含氮双膦酸盐,如唑来膦酸盐和溴羟丙焦磷酸盐(BrHPP)与IL-2的组合,以及使用CD 2、IFN-3、IL-12、OKT-3和IL-2的研究性两阶段方法。通过这些方法产生的效应细胞已经显示出针对多种人类肿瘤细胞系的有效的先天抗肿瘤活性。在本提案中,我们的目的是比较用于治疗GBM的先天性淋巴细胞治疗产品的三种FDA批准的细胞制造工艺。然后,我们将扩大规模并验证最佳生产方案,以便向FDA提交IND。该方案的总体目标,本建议将有助于进一步发展,在下面的假设。假设:同种异体先天免疫细胞,主要由34个T细胞组成的供体先天性淋巴细胞治疗产品可以使用三种FDA可批准的方法中的至少一种成功地以足够的数量制造,用于向患有脑肿瘤的患者重复顺序施用。活化的34 T细胞用于治疗多形性胶质母细胞瘤(GBM)。我们将优先考虑临床规模生产方案的开发,包括(a)细胞产品的最终组成,(B)程序的重现性,(c)效价和(d)快速翻译的可行性,如下所述,并在研究计划中详述。这一特定目标的成功完成将导致细胞治疗产品制造的可扩展程序,可由美国FDA批准用于临床。其次,我们将根据小规模工作的数据开发和验证临床规模细胞治疗产品的生产方案。完成这项工作还将包括为IND申请开发CMC部分。
公共卫生相关性:目前,多形性胶质母细胞瘤(GBM)是最常见的恶性脑肿瘤,尚无有效的治疗方法。GBM肿瘤很容易被称为34 T细胞的免疫系统成分杀死。这些细胞可以从健康供体的血液中获得,并且当暴露于促进细胞生长和免疫应答的试剂时,已经显示出杀死GBM肿瘤。我们将测试从健康供体产生34 T细胞的有前途的方法,以确定临床生产和人体治疗试验的最佳方法。
英文摘要
DESCRIPTION (provided by applicant): Despite significant advances in the treatment of cancer over the past several decades, there are no long-term effective therapies for glioblastoma multiforme (GBM). Our laboratory has recently shown promising findings both in vitro and in mouse xenograft models that human GBM is vulnerable to locally delivered allogeneic innate lymphocyte therapy. These proposed studies will define a manufacturing regimen for an FDA-approvable cell therapy product that is principally composed of expanded/activated 34 T cells and a minor subset of NK cells for the adjuvant immunotherapy of GBM. Several potential methods for the large-scale expansion of 34 T cells for immunotherapeutic applications have been recently published. These include the use of clinically-approved nitrogen-containing bisphosphonates such as Zoledronate and bromohydrin pyrophosphate (BrHPP) in combination with IL-2 as well as an investigational two-stage method using CD2, IFN-3, IL-12, OKT-3, and IL-2. Effector cells generated by these methods have shown potent innate antitumor activity against a wide variety of human tumor cell lines. In this proposal, it is our objective to compare three FDA-approvable cell manufacturing processes for an innate lymphocyte cell therapy product for treatment of GBM. We will then scale-up and validate the optimal manufacturing regimen for IND submission to the FDA. The overall objectives of this program of which this proposal will serve to further develop is below in the following hypothesis. Hypothesis: Allogeneic innate immune cells, comprised principally of 34 T cells can be successfully manufactured in sufficient numbers for repetitive sequential administration to patients with brain tumors using at least one of three FDA-approvable processes We will compare the three clinically translatable methods discussed above for manufacturing of a donor innate lymphocyte cellular therapy product comprised principally of expanded/activated 34 T cells for therapy of glioblastoma multiforme (GBM). We will prioritize development of clinical-scale manufacturing protocols on (a) final composition of the cell product, (b) reproducibility of the procedure, (c) potency and (d) feasibility of rapid translation as described below and detailed in the Research Plan. The successful completion of this specific aim will result in a scalable procedure for cell therapy product manufacturing that can be approved by the US FDA for clinical use. Secondly, we will develop and validate manufacturing protocols for clinical scale cell therapy product(s) based on data from small scale work. Completion of this work will also include the development of a CMC section for IND application.
PUBLIC HEALTH RELEVANCE: At present, there is no effective treatment for glioblastoma multiforme (GBM), the most common malignant brain tumor. GBM tumors are vulnerable to killing by a component of the immune system known as 34 T cells. These cells can be obtained from the blood of a healthy donor and, when exposed to reagents that promote cell growth and immune response, have been shown to kill GBM tumors. We will test promising methods for generating 34 T cells from healthy donor to determine the best method for clinical production and human therapeutic trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Tissue/Pathology Core
-
批准号:7727558
-
项目类别:
-
资助金额:$23.15万
-
财政年份:2009
-
负责人:LAWRENCE S LAMB
-
依托单位:
Feasibility of gamma/delta T cell immunotherapy for glioblastoma
-
批准号:7487823
-
项目类别:
-
资助金额:$15.86万
-
财政年份:2007
-
负责人:LAWRENCE S LAMB
-
依托单位:
Feasibility of gamma/delta T cell immunotherapy for glioblastoma
-
批准号:7313172
-
项目类别:
-
资助金额:$15.86万
-
财政年份:2007
-
负责人:LAWRENCE S LAMB
-
依托单位:
Feasibility of gamma/delta T cell immunotherapy for glioblastoma
-
批准号:7869514
-
项目类别:
-
资助金额:$7.12万
-
财政年份:2007
-
负责人:LAWRENCE S LAMB
-
依托单位:
BD BIOSCIENCES FACS CANTO FLOW CYTOMETER: AIDS
-
批准号:7335103
-
项目类别:
-
资助金额:$5.24万
-
财政年份:2006
-
负责人:LAWRENCE S LAMB
-
依托单位:
BD BIOSCIENCES FACS CANTO FLOW CYTOMETER: SICKLE CELL DISEASE, GENE THERAPY
-
批准号:7335105
-
项目类别:
-
资助金额:$1.75万
-
财政年份:2006
-
负责人:LAWRENCE S LAMB
-
依托单位:
BD BIOSCIENCES FACS CANTO FLOW CYTOMETER; IMMUNOLOGY, CELL BIOLOGY
-
批准号:7335107
-
项目类别:
-
资助金额:$5.24万
-
财政年份:2006
-
负责人:LAWRENCE S LAMB
-
依托单位:
BD BIOSCIENCES FACS CANTO FLOW CYTOMETER: CANCER: MELANOMA, GLIOMA
-
批准号:7335104
-
项目类别:
-
资助金额:$3.49万
-
财政年份:2006
-
负责人:LAWRENCE S LAMB
-
依托单位:
BD Biosciences FACS Canto Flow Cytometer
-
批准号:7046224
-
项目类别:
-
资助金额:$17.46万
-
财政年份:2006
-
负责人:LAWRENCE S LAMB
-
依托单位:
BD BIOSCIENCES FACS CANTO FLOW CYTOMETER: MOUSE STEM CELLS: ADULT & EMBRYONIC
-
批准号:7335106
-
项目类别:
-
资助金额:$1.75万
-
财政年份:2006
-
负责人:LAWRENCE S LAMB
-
依托单位:
ANTILEUKEMIC EFFECT OF GAMMA/DELTA T CELLS
-
批准号:6350268
-
项目类别:
-
资助金额:$10.94万
-
财政年份:2000
-
负责人:LAWRENCE S LAMB
-
依托单位:
ANTILEUKEMIC EFFECT OF GAMMA/DELTA T CELLS
-
批准号:6041896
-
项目类别:
-
资助金额:$10.57万
-
财政年份:2000
-
负责人:LAWRENCE S LAMB
-
依托单位:
ANTILEUKEMIC EFFECT OF GAMMA/DELTA T CELLS
-
批准号:6433692
-
项目类别:
-
资助金额:$2.02万
-
财政年份:2000
-
负责人:LAWRENCE S LAMB
-
依托单位:
Tissue/Pathology Core
-
批准号:8182336
-
项目类别:
-
资助金额:$21.75万
-
财政年份:--
-
负责人:LAWRENCE S LAMB
-
依托单位:
Tissue and Pathology/Immunology Core
-
批准号:9792858
-
项目类别:
-
资助金额:$12.84万
-
财政年份:--
-
负责人:LAWRENCE S LAMB
-
依托单位:
Tissue/Pathology Core
-
批准号:8379255
-
项目类别:
-
资助金额:$23.27万
-
财政年份:--
-
负责人:LAWRENCE S LAMB
-
依托单位:
Tissue/Pathology Core
-
批准号:8326156
-
项目类别:
-
资助金额:$23.01万
-
财政年份:--
-
负责人:LAWRENCE S LAMB
-
依托单位:
Tissue/Pathology Core
-
批准号:8537835
-
项目类别:
-
资助金额:$22.76万
-
财政年份:--
-
负责人:LAWRENCE S LAMB
-
依托单位:
海外基金